IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 1011.40, up by 7.70 points or 0.77% from its previous closing of Rs. 1003.70 on the BSE.

The scrip opened at Rs. 1015.00 and has touched a high and low of Rs. 1018.30 and Rs. 1002.70 respectively. So far 8750 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1150.00 on 18-Dec-2020 and a 52 week low of Rs. 641.55 on 23-Apr-2020.

Last one week high and low of the scrip stood at Rs. 1048.00 and Rs. 974.50 respectively. The current market cap of the company is Rs. 19821.43 crore.

The promoters holding in the company stood at 69.48%, while Institutions and Non-Institutions held 17.53% and 12.99% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Sinequan Capsules 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of Pfizer Inc. (Pfizer).

Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg have an estimated market size of $ 41 million for twelve months ending December 2020. Alembic has a cumulative total of 141 ANDA approvals (124 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.